Claim Amendments

1(previously presented). A compound of Formula (I) or (II)



(I)



(II)

wherein

A is nitrogen and B is carbon;

R^0 is an aryl optionally substituted with one or more substituents or a heteroaryl optionally substituted with one or more substituents;

R^1 is aryl optionally substituted with one or more substituents, heteroaryl optionally substituted with one or more substituents, $-CH=CH-R^{1a}$, or $-CH_2CH_2-R^{1a}$, where R^{1a} is hydrogen or a chemical moiety selected from (C_1-C_8)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring(s), 3- to 6-membered partially or fully saturated heterocycle, aryl, heteroaryl, where the chemical moiety is optionally substituted with one or more substituents;

X is a bond;

R^{3a} and R^{3b} are each independently hydrogen, (C_1-C_4)alkyl, or halo-substituted (C_1-C_4)alkyl; and

R^4 is a chemical moiety selected from the group consisting of (C_1-C_8)alkyl, aryl, heteroaryl, aryl(C_1-C_4)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C_1-C_3)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound, or said salt:

provided that when the compound is a compound of Formula (II), R^{3a} and R^{3b} are not both hydrogen when X is a bond.

2(original). The compound of Claim 1 wherein R^4 is a chemical moiety selected from the group consisting of $(C_1$-$C_8)$alkyl, aryl$(C_1$-$C_4)$alkyl, and 3- to 8-membered partially or fully saturated carbocyclic ring(s), and 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

3(original). The compound of Claim 2 wherein R^4 is $(C_1$-$C_8)$alkyl, halo-substituted $(C_1$-$C_8)$alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-1-yl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

4(original). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (I);

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

5-6(cancelled).

7(previously presented). The compound of Claim 4 wherein R^0 and R^1 are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkyl, halo-substituted $(C_1$-$C_4)$alkyl, and cyano;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

8(original). The compound of Claim 7 wherein R^0 and R^1 are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkyl, fluoro-substituted $(C_1$-$C_4)$alkyl), and cyano;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

9(original). The compound of Claim 8 wherein R^0 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R^1 is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

10(previously presented). The compound of Claim 4 selected from the group consisting of

2-(2-chloro-phenyl)-5-isopropyl-3-(4-methoxy-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

2-(2-chloro-phenyl)-5-isopropyl-3-(4-cyano-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

2-(2-chloro-phenyl)-5-isopropyl-3-(4-chloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-cyclohexyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-isopropyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-5-cyclohexyl-2-(2,4-dichloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-isopropyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-cyano-phenyl)-2-(3-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one

3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one; and

3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-cyclohexyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

or a solvate or hydrate of said compound.

11(original). The compound of Claim 10 selected from the group consisting of

2-(2-chloro-phenyl)-5-isopropyl-3-(4-cyano-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

2-(2-chloro-phenyl)-5-isopropyl-3-(4-chloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one; and

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

or a solvate or hydrate of said compound.

12-29(cancelled).

30(original). The compound of Claim 4 wherein R^1 is $-CH=CH-R^{1a}$, or $-CH_2CH_2-R^{1a}$, where R^{1a} is hydrogen or a chemical moiety selected from (C_1-C_8)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring(s), 3- to 6-membered partially or fully saturated heterocycle, aryl, heteroaryl, where the chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

31(original). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (II);

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

32-33(cancelled).

34(previously presented). The compound of Claim 31 wherein R^0 and R^1 are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, and cyano;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

35(original). The compound of Claim 34 wherein R^0 and R^1 are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, $(C_1\text{-}C_4)$alkoxy, $(C_1\text{-}C_4)$alkyl, fluoro-substituted $(C_1\text{-}C_4)$alkyl), and cyano;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

36(original). The compound of Claim 35 wherein R^0 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R^1 is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

37-41(cancelled).

42(previously presented). A compound of Formula (III) or (IV)



(III)



(IV)

wherein

A is nitrogen and B is carbon;

R^{0a}, R^{0b}, R^{1a}, and R^{1b} are each independently halo, (C_1-C_4)alkoxy, (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, or cyano;

n and m are each independently 0, 1 or 2;

X is a bond;

R^{3a} and R^{3b} are each independently hydrogen, (C_1-C_4)alkyl, or halo-substituted (C_1-C_4)alkyl; and

R^4 is a chemical moiety selected from the group consisting of (C_1-C_8)alkyl, aryl, heteroaryl, aryl(C_1-C_4)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C_1-C_3)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt:

provided that when said compound is a compound of Formula (IV), R^{3a} and R^{3b} are not both hydrogen when X is a bond.

43(original). The compound of Claim 42 wherein said compound is a compound of Formula (III);

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

44-48(cancelled).

49(original). The compound of Claim 42 wherein said compound is a compound of Formula (IV);

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

50-54(cancelled).

55(original). A pharmaceutical composition comprising (1) a compound of Claim 1, or a solvate or hydrate of said compound or said salt; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

56-58(cancelled).

59(previously presented). A method for treating obesity comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 1;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

60-63 (cancelled).

64(previously presented). A method for treating obesity comprising the step of administering a pharmaceutical composition of Claim 55.

65 – 73 (cancelled).